Stora Enso Oyj financials
Stora Enso Oyj
Country: FI Reporting currency: EUR Latest annual report: 2025-12-31
LEI:
7437000ZP669LKUTZ738 Financial statements
(EUR, as reported — unscaled; 120 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €9.33B | €9.05B |
| Employee benefits expense | €1.23B | €1.23B |
| Raw materials & consumables used | €7.02B | €6.74B |
| Operating profit (EBIT) | €942.0M | €93.0M |
| Finance costs | €263.0M | €329.0M |
| Profit before tax | €783.0M | -€118.0M |
| Income tax expense | €97.0M | €65.0M |
| Profit for the year | €686.0M | -€183.0M |
| — attributable to owners | €695.0M | -€136.0M |
| — attributable to NCI | -€9.0M | -€48.0M |
| Total comprehensive income | €857.0M | -€738.0M |
| Per share | ||
| Basic EPS | €0.88 | €-0.17 |
| Diluted EPS | €0.88 | €-0.17 |
| Free cash flow / share | €-0.04 | €-0.05 |
| Cash flow statement | ||
| Cash generated from operations | €897.0M | €1.19B |
| Net cash from operating activities | €645.0M | €952.0M |
| Net cash from investing activities | €60.0M | -€1.13B |
| Net cash from financing activities | -€1.49B | -€301.0M |
| Dividends paid | €209.0M | €146.0M |
| Net change in cash | -€783.0M | -€483.0M |
| Balance sheet | ||
| Total assets | €19.06B | €19.80B |
| Non-current assets | €15.08B | €15.08B |
| Right-of-use assets | €422.0M | €499.0M |
| Intangible assets & goodwill | €171.0M | €162.0M |
| Inventories | €1.80B | €1.67B |
| Trade & other receivables | €869.0M | €969.0M |
| Cash & equivalents | €1.21B | €2.00B |
| Total equity | €10.65B | €9.99B |
| — attributable to owners | €10.80B | €10.14B |
| Non-controlling interests | -€147.0M | -€150.0M |
| Non-current liabilities | €5.13B | €5.58B |
| Current portion of long-term borrowings | €253.0M | €1.09B |
| Trade & other payables | €2.29B | €2.30B |
| Deferred tax liabilities | €1.31B | €1.42B |
| Derived metrics | ||
| Free cash flow | -€34.0M | -€58.0M |
| Operating margin | 10.1% | 1.0% |
| Net margin | 7.4% | -2.0% |
| Return on equity | 6.4% | -1.8% |
| Cash conversion ratio | 0.94× | -5.20× |
| Capex coverage | 0.95× | 0.94× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€53.0M | -€136.0M |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €507.0M | €1.25B |
| Adjustments For Gains Losses On Change In Fair Value Less Costs To Sell Biological Assets | €401.0M | €421.0M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | -€155.0M | -€3.0M |
| Adjustments For Sharebased Payments | €2.0M | -€2.0M |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | €89.0M | €52.0M |
| Bank Overdrafts Classified As Cash Equivalents | €5.0M | €7.0M |
| Cash | €693.0M | €912.0M |
| Cash and Cash Equivalents If Different From Statement of Financial Position | €1.21B | €1.99B |
| Cash Equivalents | €519.0M | €1.09B |
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €619.0M | €8.0M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €17.0M | €75.0M |
| Comprehensive Income Attributable To Noncontrolling Interests | €3.0M | -€53.0M |
| Comprehensive Income Attributable To Owners of Parent | €854.0M | -€685.0M |
| Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | €3.98B | €4.72B |
| Current Liabilities Other Than Liabilities Included In Disposal Groups Classified As Held For Sale | €3.28B | €4.23B |
| Current Provisions | €50.0M | €37.0M |
| Current Tax Assets Current | €29.0M | €31.0M |
| Current Tax Liabilities Current | €17.0M | €13.0M |
| Deferred Tax Assets | €222.0M | €205.0M |
| Depreciation Amortisation and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €507.0M | €1.25B |
| Dividends Received Classified As Operating Activities | €29.0M | €29.0M |
| Dividends Recognised As Distributions To Owners Per Share | €0.25 | €0.20 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€4.0M | €11.0M |
| Equity and Liabilities | €19.06B | €19.80B |
| Finance Income | €104.0M | €118.0M |
| Gains Losses On Change In Fair Value Estimates of Biological Assets For Current Period | €401.0M | €421.0M |
| Income Tax Relating To Components of Other Comprehensive Income | €53.0M | €72.0M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | €20.0M | -€19.0M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | -€73.0M | -€53.0M |
| Income Taxes Paid Refund Classified As Operating Activities | €48.0M | €73.0M |
| Increase Decrease In Working Capital | -€51.0M | -€283.0M |
| Increase Decrease Through Sharebased Payment Transactions | €2.0M | -€1.0M |
| Increase Decrease Through Treasury Share Transactions | -€2.0M | -€3.0M |
| Intangible Assets Other Than Goodwill | €250.0M | €277.0M |
| Interest Paid Classified As Operating Activities | €192.0M | €197.0M |
| Interest Received Classified As Operating Activities | €33.0M | €77.0M |
| Investment Accounted For Using Equity Method | €1.11B | €954.0M |
| Issued Capital | €1.34B | €1.34B |
| Liabilities | €8.41B | €9.81B |
| Miscellaneous Other Operating Expense | €503.0M | €543.0M |
| Miscellaneous Other Operating Income | €389.0M | €325.0M |
| Noncurrent Biological Assets | €5.17B | €5.24B |
| Noncurrent Financial Assets | €14.0M | €14.0M |
| Noncurrent Financial Liabilities | €3.56B | €3.89B |
| Noncurrent Provisions For Employee Benefits | €153.0M | €181.0M |
| Other Adjustments To Reconcile Profit Loss | €12.0M | €15.0M |
| Other Cash Payments To Acquire Equity Or Debt Instruments of Other Entities Classified As Investing Activities | €1.0M | €0 |
| Other Comprehensive Income Attributable To Noncontrolling Interests | €12.0M | -€5.0M |
| Other Comprehensive Income Before Tax | €118.0M | -€626.0M |
| Other Comprehensive Income Before Tax Cash Flow Hedges | €84.0M | -€81.0M |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | €124.0M | -€89.0M |
| Other Comprehensive Income Before Tax Gains Losses From Investments In Equity Instruments | €297.0M | -€202.0M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €36.0M | €22.0M |
| Other Comprehensive Income Before Tax Gains Losses On Revaluation | -€385.0M | -€281.0M |
| Other Comprehensive Income Before Tax Hedges of Net Investments In Foreign Operations | -€21.0M | €4.0M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | €179.0M | -€152.0M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -€8.0M | -€403.0M |
| Other Current Financial Assets | €67.0M | €47.0M |
| Other Current Financial Liabilities | €659.0M | €788.0M |
| Other Equity Interest | €633.0M | €633.0M |
| Other Inflows Outflows of Cash Classified As Operating Activities | -€45.0M | -€43.0M |
| Other Longterm Provisions | €79.0M | €81.0M |
| Other Noncurrent Assets | €69.0M | €53.0M |
| Other Noncurrent Liabilities | €30.0M | €10.0M |
| Other Property Plant and Equipment | €5.23B | €5.01B |
| Other Reserves | €1.71B | €1.81B |
| Payments To Acquire Or Redeem Entitys Shares | €2.0M | €3.0M |
| Proceeds From Disposals of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €17.0M | €23.0M |
| Proceeds From Noncurrent Borrowings | €489.0M | €19.0M |
| Proceeds From Sales of Investments Accounted For Using Equity Method | €1.0M | €0 |
| Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities | €9.0M | €3.0M |
| Purchase of Biological Assets | €96.0M | €103.0M |
| Purchase of Interests In Investments Accounted For Using Equity Method | €0 | €1.0M |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €679.0M | €1.01B |
| Reserve of Exchange Differences On Translation | -€357.0M | -€457.0M |
| Retained Earnings | €7.39B | €6.74B |
| Share of Other Comprehensive Income of Associates and Joint Ventures Accounted For Using Equity Method That Will Not Be Reclassified To Profit Or Loss Before Tax | -€28.0M | €5.0M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | €89.0M | €52.0M |
| Share Premium | €77.0M | €77.0M |
Methodology
Every line item above is a fact tagged in Stora Enso Oyj's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.